The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Beneficial Antipsychotic Effects of Celecoxib Add-On Therapy Compared to Risperidone Alone in Schizophrenia
Abstract
OBJECTIVE: Abnormalities in the immune system in schizophrenia have been described. However, important findings such as high levels of activating cytokines in the CSF and signs of CNS inflammation have been controversial. The authors conducted a trial of the new selective cyclooxygenase-2 inhibitor celecoxib, an immunomodulatory drug, in schizophrenic patients to evaluate its therapeutic effects. METHOD: In a prospective, double-blind evaluation, 50 patients with an acute exacerbation of schizophrenia were randomly assigned to either risperidone plus celecoxib or risperidone plus placebo. After a washout period, 25 patients received 2-6 mg/day of risperidone plus placebo and 25 received risperidone plus 400 mg/day of celecoxib for 5 weeks. The treatment effect was calculated by analysis of covariance. There were no significant differences between groups in age, sex, duration or severity of disease or psychopathology, or risperidone dose or plasma level. RESULTS: Over 5 weeks, both groups of patients showed significant improvement in scores on the Positive and Negative Syndrome Scale and on all subscales. However, the celecoxib group showed significantly greater improvement in the total score. CONCLUSIONS: Additional treatment with celecoxib has significant positive effects on the therapeutic action of risperidone with regard to total schizophrenia psychopathology. Moreover, the fact that treatment with an immunomodulatory drug showed beneficial effects on schizophrenia symptoms indicates that immune dysfunction in schizophrenia is not just an epiphenomenon but is related to the pathomechanism of the disorder. However, a nonimmunological therapeutic effect of celecoxib mediated by the N-methyl-D-aspartic acid receptor has to be taken into account.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
SIMPSON, G. M., B., M., B., G., ANGUS, J. W. S., P., F. R. C., & M., D. P. (1970) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1970.tb02066.x · Cited by 3,264
Yamagata, K., Andreasson, K. I., Kaufmann, W. E., Barnes, C. A., & Worley, P. F. (1993) · Neuron · doi:10.1016/0896-6273(93)90192-t · Cited by 1,226
Risperidone in the treatment of schizophrenia
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.6.825 · Cited by 1,193
Cyclo-Oxygenase-2 Gene Expression in Neurons Contributes to Ischemic Brain Damage
Nogawa, S., Zhang, F., Ross, M. E., & Iadecola, C. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02746.1997 · Cited by 716
Maes, M., Bosmans, E., Calabrese, J., Smith, R., & Meltzer, H. Y. (1995) · Journal of Psychiatric Research · doi:10.1016/0022-3956(94)00049-w · Cited by 385
Viruses, schizophrenia, and bipolar disorder
Yolken, R. H., & Torrey, E. F. (1995) · Clinical Microbiology Reviews · doi:10.1128/cmr.8.1.131 · Cited by 356
The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6
Lin, A., Kenis, G., Bignotti, S., Tura, G.-J.-B., De Jong, R., Bosmans, E., Pioli, R., Altamura, C., Scharpé, S., & Maes, M. (1998) · Schizophrenia Research · doi:10.1016/s0920-9964(98)00034-6 · Cited by 321
Psychoneuroimmunology and the cytokine action in the CNS: Implications for psychiatric disorders
Müller, N., & Ackenheil, M. (1998) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(97)00179-6 · Cited by 306
Self-citationHewett, S. J., Uliasz, T. F., Vidwans, A. S., & Hewett, J. A. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)39251-1 · Cited by 227
(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.9.1291 · Cited by 204
Baik, E. J., Kim, E. J., Lee, S. H., & Moon, C.-H. (1999) · Brain Research · doi:10.1016/s0006-8993(99)01797-7 · Cited by 200
Breder, C. D., & Saper, C. B. (1996) · Brain Research · doi:10.1016/0006-8993(95)01474-8 · Cited by 197
Elevated CSF levels of interleukin-2 in neuroleptic-free schizophrenic patients
(1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.9.1408 · Cited by 185
Müller, N., Empl, M., Riedel, M. J., Schwarz, M., & Ackenheil, M. (1997) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/bf02922260 · Cited by 127
Self-citationMcGeer, P. L. (2000) · Drugs & Aging · doi:10.2165/00002512-200017010-00001 · Cited by 118
Müller, N. (1995) · Schizophrenia Research · doi:10.1016/0920-9964(94)00045-a · Cited by 117
Self-citationSchwarz, M., Riedel, M. J., Ackenheil, M., & Müller, N. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00206-1 · Cited by 96
Self-citationCyclooxygenases in the Central Nervous System: Implications for Treatment of Neurological Disorders
Yermakova, A., & O’Banion, M. K. (2000) · Current Pharmaceutical Design · doi:10.2174/1381612003398672 · Cited by 93
Körschenhausen, D. A., Hampel, H. J., Ackenheil, M., Penning, R., & Müller, N. (1996) · Schizophrenia Research · doi:10.1016/0920-9964(95)00073-9 · Cited by 86
Self-citationKlegeris, A., Walker, D. G., & McGeer, P. L. (1999) · Neuropharmacology · doi:10.1016/s0028-3908(99)00014-3 · Cited by 75
ller, N. M. ⁄., Riedel, M. J., Hadjamu, M., Schwarz, M., Ackenheil, M., & Gruber, R. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.4.634 · Cited by 72
Self-citationIncreased interleukin-1 and interleukin-3 like activity in schizophrenic patients
Sirota, P. (1995) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(94)00106-r · Cited by 64
Soluble IL-6 receptors in the serum and cerebrospinal fluid of paranoid schizophrenic patients
Müller, N., Dobmeier, P., Empl, M., Riedel, M. J., Schwarz, M., & Ackenheil, M. (1997) · European Psychiatry · doi:10.1016/s0924-9338(97)84789-x · Cited by 62
Self-citationBlood–cerebrospinal fluid barrier impairment as indicator for an immune process in schizophrenia
Schwarz, M., Ackenheil, M., Riedel, M. J., & Müller, N. (1998) · Neuroscience Letters · doi:10.1016/s0304-3940(98)00655-7 · Cited by 51
Self-citationMöller, H. ‐., Gagiano, C. A., Addington, D. E., von Knorring, L., Torres-Planks, J. F., & Gaussarès, C. (1998) · International Clinical Psychopharmacology · doi:10.1097/00004850-199805000-00001 · Cited by 51
Self-citationBishop‐Bailey, D., Burke-Gaffney, A. C., Hellewell, P. G., Pepper, J., & Mitchell, J. A. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.8966 · Cited by 43
Relationship between immune and behavioral measures in schizophrenia
van Kammen, D. P., McAllister, C. G., & Kelley, M. E. (1997) · Key topics in brain research · doi:10.1007/978-3-7091-6870-7_7 · Cited by 39
Cited by
Meta-Analysis of Cytokine Alterations in Schizophrenia: Clinical Status and Antipsychotic Effects
Miller, B. J., Buckley, P., Seabolt, W., Mellor, A., & Kirkpatrick, B. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.04.013 · Cited by 1,742
Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment
Khandaker, G. M., Cousins, L., Deakin, J., Lennox, B. R., Yolken, R., & Jones, P. B. (2015) · The Lancet Psychiatry · doi:10.1016/s2215-0366(14)00122-9 · Cited by 926
Khandaker, G. M., Pearson, R. M., Zammit, S., Lewis, G., & Jones, P. B. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.1332 · Cited by 846
Müller, N., Schwarz, M. J., Dehning, S., Douhe, A., Cerovecki, A., Goldstein-Müller, B., Spellmann, I., Hetzel, G., Maino, K., Kleindienst, N., et al. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001805 · Cited by 794
Self-citationNeuroinflammation and psychiatric illness
Najjar, S., Pearlman, D. M., Alper, K., Najjar, A., & Devinsky, O. (2013) · Journal of Neuroinflammation · doi:10.1186/1742-2094-10-43 · Cited by 733
“Several additional experimental and human studies examined in more detail the mechanisms underlying the pathophysiology of increased oxidative stress in psychiatric disorders [206-262].”
Metadata
- Authors
- Müller, N., Riedel, M., Scheppach, C., Brandstätter, B., Sokullu, S., Krampe, K., Ulmschneider, M., Engel, R. R., Möller, H.-J., & Schwarz, M. J.
- Venue
- American Journal of Psychiatry
- Published
- 2002-06-01
- Volume
- 159
- Issue
- 6
- Pages
- 1029-1034
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2171149822
- Cited by
- 388
- References
- 28
- FWCI
- 7.88
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.